Human studies, up front
Human Studies, Up Front
Ten human trials of hydrogen-rich water, each linked to the original paper on PubMed with its finding and its limits side by side. Roughly 900 participants have taken part in the human trials cited on this page, across Japan, China, South Korea, Europe, the USA and India, and none of them tested a Peakspan device. These are study results, not product promises.
Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose toleranceJapan · RCT · n=30
Nutrition Research, 2008 · Kajiyama Clinic, Kyoto, randomized, double-blind, placebo-controlled crossover, 900 ml/day for 8 weeks
Modified LDL fractions fell, electronegative LDL −15.5%, small-dense LDL −5.7%, and urinary 8-isoprostanes (oxidative stress) dropped 6.6%; in 4 of 6 participants with impaired glucose tolerance, glucose-tolerance tests normalized.
Limit: n=30; surrogate blood markers, not disease outcomes; the glucose finding is a 6-person subgroup. Foundational, not definitive.
Pilot study: Effects of drinking hydrogen-rich water on muscle fatigue caused by acute exercise in elite athletesJapan · Crossover · n=10
Medical Gas Research, 2012 · University of Tsukuba, double-blind, placebo-controlled crossover in elite soccer players
Pre-exercise hydrogen-rich water prevented the rise in blood lactate during heavy exercise seen with placebo, and peak torque did not show the early decline observed in the placebo condition.
Limit: n=10 pilot; oxidative-injury markers and creatine kinase did not change; the authors call the results preliminary.
Hydrogen-rich water for improvements of mood, anxiety, and autonomic nerve function in daily lifeJapan · RCT crossover · n=26
Medical Gas Research, 2017 · Osaka City University / RIKEN, double-blind crossover, 600 ml/day, 4 weeks per arm
Psychological-distress scores (K6 scale) and resting sympathetic nervous-system activity were significantly lower after 4 weeks of hydrogen-rich water than after placebo water.
Limit: n=26; mood endpoints are subjective questionnaires; industry funding disclosed. A single small trial.
Acute Supplementation with Molecular Hydrogen Benefits Submaximal Exercise IndicesUSA/Slovakia · Crossover · n=19
Journal of Lifestyle Medicine, 2019, randomized, double-blind, placebo-controlled crossover pilot, graded treadmill test
Hydrogen-rich water significantly lowered average exercising heart rate (121 vs 126 bpm with placebo, p<0.001) and respiratory rate at submaximal intensity, without reducing oxygen uptake.
Limit: pilot, n=19; maximal performance was unchanged, the effect is a lower heart-rate cost at submaximal work.
Hydrogen-rich water reduces inflammatory responses and prevents apoptosis of peripheral blood cells in healthy adultsSouth Korea · RCT · n=38
Scientific Reports, 2020 · Seoul National University, double-blind, 1.5 L/day for 4 weeks
Apoptosis of peripheral blood mononuclear cells was significantly lower in the hydrogen group; in participants aged 30+, biological antioxidant potential increased more than with plain water, and transcriptome analysis showed downregulated inflammatory signaling.
Limit: primary oxidative-stress markers did not differ overall, the antioxidant gain was an age-subgroup finding; cellular endpoints are not clinical outcomes.
The Effects of 24-Week, High-Concentration Hydrogen-Rich Water on Body Composition, Blood Lipid Profiles and Inflammation Biomarkers in Men and Women with Metabolic SyndromeIndia/Slovakia · RCT · n=60
Diabetes, Metabolic Syndrome and Obesity, 2020, the longest trial in the field, 24 weeks, randomized, double-blind, placebo-controlled
Versus placebo: total cholesterol fell from 187.7 to 169.2 mg/dL, triglycerides dropped about 47 mg/dL, HbA1c improved about 12%, and inflammation biomarkers improved.
Limit: surrogate blood markers, not disease outcomes; a single trial of 60 people that needs independent replication at this duration.
The human evidence base is real but early-stage: concentrations in published trials (roughly 500–1,600 PPB) and daily volumes (0.5–2 L) vary widely, the field's largest trial, a 178-patient, 72-week Parkinson's RCT, was null, and null results are retained on this page deliberately. Study findings describe what specific trials measured in specific populations; they do not establish that any product diagnoses, treats, cures or prevents any disease.